YIYoshitaka Isaka

Yoshitaka Isaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshitaka Isaka has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Enyu Imai

    Osaka University Graduate School of Medicine, Departments of Nephrology and Geriatrics, Suite 565-0871, Japan

    4 shared publications
  • Shiro Takahara

    Osaka University Graduate School of Medicine, Departments of Advanced Technology for Transplantation, Suite 565-0871, Japan +81 6 6879 3746; +81 6 6879 3749

    2 shared publications
  • Yoshitsugu Takabatake

    Department of Nephrology

    2 shared publications
  • Atsushi Takahashi

    Osaka Kousei-Nenkin Hospital , Osaka

    1 shared publication
  • Chigure Suzuki

    Department of Nephrology

    1 shared publication
  • E. Imai

    Department of Nephrology, Osaka University Graduate School of Medicine (A8), Suita, Japan

    1 shared publication

Latest Publications

  • Open Access

    Exaggerated compensatory response to acute respiratory alkalosis in panic disorder is induced by increased lactic acid production

    by Yoshiyasu Ueda, Masayo Aizawa, Atsushi Takahashi, Masamitsu Fujii, Yoshitaka Isaka

    Background. In acute respiratory alkalosis, the severity of alkalaemia is ameliorated by a decrease in plasma [HCO 3− ] of 0.2 mEq/L for each 1 mmHg decrease in PaCO 2 . Although hyperventilation in panic disorder patients is frequently encountered in outpatients, the drop in plasma [HCO 3− ] sometimes surpasses the expectation calculated from the above formula. The quantitative relationship between reduced PaCO 2 and plasma [HCO 3− ] in acute respiratory alkalosis has not been studied in panic disorder patients. Our objective was to provide reference data for the compensatory metabolic changes in acute respiratory alkalosis in panic disorder patients. Methods. In 34 panic disorder patients with hyperventilation attacks, we measured arterial pH, PaCO 2 , plasma [HCO 3− ] and lactate on arrival at the emergency room. Results. For each decrease of 1 mmHg in PaCO 2 , plasma [HCO 3− ] decreased by 0.41 mEq/L. During hypocapnia, panic disorder patients exhibited larger increases in serum lactate levels (mean ± SD; 2.59 ± 1.50 mmol/L, range; 0.78–7.78 mmol/L) than previously reported in non-panic disorder subjects. Plasma lactate accumulation was correlated with PaCO 2 ( P < 0.001). Conclusions. These results suggest that the compensatory metabolic response to acute respiratory alkalosis is exaggerated by increased lactic acid production in panic disorder patients. Here, we call attention to the diagnosis of acid–base derangements by means of plasma [HCO 3− ] and lactate concentration in panic disorder patients.


  • Oligonucleotidic therapeutics

    by Yoshitaka Isaka, Enyu Imai, Shiro Takahara, Hiromi Rakugi

    (2008). Oligonucleotidic therapeutics. Expert Opinion on Drug Discovery: Vol. 3, No. 9, pp. 991-996.


  • Open Access

    Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model

    by Harumi Kitamura, Yoshitaka Isaka, Yoshitsugu Takabatake, Ryoichi Imamura, Chigure Suzuki, Shiro Takahara, Enyu Imai

    Background. Erythropoietin (EPO), a member of the cytokine type I superfamily, acts to increase circulating erythrocytes primarily by preventing apoptosis of erythroid progenitors, is known to protect tissues and can raise haemoglobin (Hb) concentrations. Recently, a second receptor for EPO comprising the EPO receptor and β-common receptor has been reported to mediate EPO-induced tissue protection. EPO modified by carbamylation (CEPO) only signals through this second receptor. Accordingly, we hypothesized that treatment with CEPO, which would not increase Hb concentrations, would protect against tubular damage and thereby inhibit tubulointerstitial injuries. Methods. We evaluated therapeutic effects of CEPO using a rat unilateral ureteral obstruction model. Results. CEPO decreased tubular apoptosis and α-smooth muscle actin (αSMA) expression in the absence of polycythaemia, while the untreated obstructed kidneys exhibited increased tubular apoptosis with expanded (αSMA) expression. While EPO treatment similarly inhibited tubular apoptosis and αSMA expression, EPO treatment increased Hb concentrations and induced a wedge-shaped infarction. Conclusion. We established a therapeutic approach using CEPO to protect against tubulointerstitial injury. The therapeutic value of this approach warrants further attention and preclinical studies.


  • Open Access

    Renal artery injection for delivery of biological materials to the glomerulus (Methods in Renal Research Paper)

    by Yoshitsugu Takabatake, Yoshitaka Isaka, Enyu Imai

    SUMMARY: Aim:  We investigated whether injection of synthetic small interfering siRNAs via renal artery followed by electroporation could be effective in silencing specific genes in glomerulus.Methods:  Solution of siRNA targeting enhanced green fluorescent protein (EGFP) was injected via the renal artery of EGFP‐transgenic rats followed by delivery of electric pulses.Results:  The delivery of siRNA reduced endogenous EGFP expression, mainly in glomerular mesangial cells.Conclusion:  Electroporation‐mediated gene transfer system via renal artery in rats is very useful for the delivery of a range of different materials including cells, viruses and proteins. Here, we provide a step‐by‐step description of this perfusion method and a discussion of the key points for the success of the technique.


  • Electroporation-mediated gene therapy

    by Yoshitaka Isaka, Enyu Imai

    (2007). Electroporation-mediated gene therapy. Expert Opinion on Drug Delivery: Vol. 4, No. 5, pp. 561-571.


    • 1 April 2007
      • Vol. 9  (2) , 132-6

    DNAzymes as potential therapeutic molecules.

    by Yoshitaka Isaka

    Numerous DNA-based biopharmaceuticals are able to control disease progression by induction and/or inhibition of genes. These potent therapeutics include plasmids containing transgenes, antisense oligonucleotides, aptamers, ribozymes, DNAzymes and short interfering RNAs. DNAzymes, which cleave RNA substrates in a sequence-specific manner, have been studied as potential therapeutics to target pathogenic mRNAs, and may yield drugs that are safer than those currently available. This reviewo discusses the structural design of DNAzymes and their modification for stability. Their therapeutic application and use as biomarkers is also discussed.


  • Gene therapy targeting kidney diseases: routes and vehicles

    by Yoshitaka Isaka

    Renal gene therapy may offer new strategies to treat diseases of native and transplanted kidneys. Several experimental techniques have been developed and employed using nonviral, viral, and cellular vectors. The most efficient viral vector for in vivo transfection appears to be adenovirus. In addition, enhanced naked plasmid techniques, such as the hemagglutinating virus of Japan (HVJ)-liposome method, electroporation, the hydrodynamic method, and ultrasound with microbubbles, are promising. Trapping genetically modified macrophages in the inflamed kidneys is an elegant method for site-specific gene delivery. The choice of delivery vehicle as well as the administration route determines the site of transduction. In conclusion, for both in vivo and ex vivo renal transfection, enhanced naked plasmids, adenoviruses, and modified cell vectors offer the best prospects for effective clinical application. Moreover, the development of safer and nonimmunogenic vectors may realize clinical renal gene therapy in the near future.


  • Transcription factor Ets-1 is essential for mesangial matrix remodeling

    by M. Mizui, Y. Isaka, Y. Takabatake, Y. Sato, H. Kawachi, F. Shimizu, S. Takahara, T. Ito, E. Imai


  • HGF gene transfer increases kidney graft survival

    by Yoshitaka Isaka, Kazuhiko Yamada